An Inducible, multiplexed CRISPR system

Reference number 11009

Sectors: Biotechnology

Industries: Biotechnology

A CRISPR-based platform for inducibly up- and down-regulating up to 24 genes in the yeast, Saccharomyces cerevisiae.

Proposed use

This innovation addresses concerns related to potential disruptions in gene expression during the transformation process, particularly for genes critical to growth or essential processes. The proposed approach is anticipated to empower researchers to target genes within the Saccharomyces cerevisiae genome without undesirable effects on their expression during transformation and handling without an inducer. This breakthrough opens avenues for studying essential genes and combinations thereof, potentially uncovering synthetic lethality relationships.

Problem addressed

Slow genetic manipulation and low multiplexity are significant limitations in current metabolic engineering methods. These limitations hinder the ability to efficiently design and optimize microbial strains for various biotechnological applications, including the production of biofuels, chemicals, pharmaceuticals, and other valuable compounds.

Technology overview

This is a novel reversible array repression technique that enables the encoding of multiple guide RNAs (gRNAs) on a single transcript with precise control over their expression. The utilization of mutTetR ensures robust repression, effectively silencing the array when in the off state. Conversely, the activation of TetA leads to strong expression, facilitating transcription of the entire array in the on state. This dynamic regulation results in a significant fold-change in the expression of target genes. The strategic silencing of the array when not in use is expected to streamline the process of transforming CRISPRai constructs, promoting better growth in the absence of the inducer.


  • Allow inducibility with no leakiness for the first time
  • Inducible up- and down-regulation of up to 24 genes
  • Quick and easy design and assembly of gRNA arrays
  • Optimised for low burden
  • Entire system delivered on single construct, compatible with all common lab strains
  • Available with 10 selectable markers

Intellectual property information

Patent: WO 2023/148491



Dr Rodrigo Ledesma Amaro


Visit personal site

Contact us about this technology


Diana Yin

Industry Partnerships and Commercialisation Executive, Engineering

Diana supports and leads on the commercialisation of MedTech, and HealthTech related technologies from Imperial’s Faculty of Engineering

Contact Diana

[email protected]

Related technologies

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

A real-time fluorescence probe for Heme Oxygenase activity

A real-time fluorescence probe for Heme Oxygenase activity

Novel heme oxygenase 1 (HO-1) probe compositions, and methods covering easy-to-use and rapid readouts of cell protection in cardiovascular diseases, hemorrhage and red cell disorders. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.